Switching from Remicade to Inflectra for Crohn's Disease in Clinical Remission

Patient Clinical Context

• A 23-year-old male with Crohn's disease affecting both small and large intestine has normal laboratory values 1
• The patient has stable drug levels without antibodies 2
• The patient has normal laboratory values 1

Rationale for Biosimilar Switch

• Clinical guidelines support switching from originator infliximab to biosimilars in patients with stable disease, according to the British Society of Gastroenterology 3
• The British Society of Gastroenterology guidelines note that biosimilar switching is appropriate in stable patients, with measurement of drug levels potentially helpful before switching 3

Evidence Supporting Biosimilar Use

• Maintaining the higher dose (10mg/kg vs standard 5mg/kg) is appropriate given previous disease activity despite treatment 4
• Stable drug levels without antibodies support maintaining the higher dose 2
• The patient's stable drug levels without antibodies are consistent with guidelines from the British Society of Gastroenterology 2

Important Considerations for Implementation

• Monitor the patient closely after switching, particularly at the first infusion after the change, as recommended by the British Society of Gastroenterology 3
• Continue regular laboratory monitoring as previously scheduled, according to guidelines 1
• Maintain the same dosing schedule to minimize risk of immunogenicity, as recommended by the Journal of Crohn's and Colitis 4

Potential Pitfalls and How to Avoid Them

• Risk of immunogenicity can be mitigated by continuing regular monitoring of drug levels and antibodies, as recommended by the British Society of Gastroenterology 2
• Loss of response can be managed by checking drug levels and antibodies if clinical symptoms develop after switching, according to guidelines 1